Last reviewed · How we verify
Anti-CD5 CAR NK cells
Anti-CD5 CAR T cells target and kill cancer cells by binding to the CD5 receptor on their surface.
Anti-CD5 CAR T cells target and kill cancer cells by binding to the CD5 receptor on their surface. Used for Relapsed or refractory B-cell malignancies.
At a glance
| Generic name | Anti-CD5 CAR NK cells |
|---|---|
| Sponsor | Chongqing Precision Biotech Co., Ltd |
| Drug class | CAR T cell therapy |
| Target | CD5 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
This mechanism involves the use of chimeric antigen receptor (CAR) T cells that are engineered to recognize and bind to the CD5 receptor on cancer cells, leading to their destruction.
Approved indications
- Relapsed or refractory B-cell malignancies
Common side effects
- Cytokine release syndrome
- Neutropenia
- Anemia
Key clinical trials
- Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-CD5 CAR NK cells CI brief — competitive landscape report
- Anti-CD5 CAR NK cells updates RSS · CI watch RSS
- Chongqing Precision Biotech Co., Ltd portfolio CI